C
TBPH icon

Chescapmanager’s Theravance Biopharma TBPH Stock Holding History

Chescapmanager’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-91,700
Closed -$1.79M – 35
2019
Q3 		$1.79M Hold
91,700
– – 0.25% 30
2019
Q2 		$1.5M Buy
+91,700
New +$1.86M 0.15% 38

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Chescapmanager's TBPH Position: Q3 2024 in Review

Chescapmanager sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 96,197 shares — an estimated $816K sold.

Chescapmanager first reported a position in TBPH in Q4 2016 and held it in 31 quarters. The position peaked at $24.6M in Q4 2019. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

  • Chescapmanager reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
  • Chescapmanager sold 96,197 Theravance Biopharma shares in Q3 2024, an estimated $816K.
  • Chescapmanager first reported a position in Theravance Biopharma in Q4 2016 and held it in 31 quarters.
  • Chescapmanager's Theravance Biopharma position peaked at $24.6M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Chescapmanager's 13F filing for Q3 2024, filed 14 Nov 2024.